For the quarter ending 2026-03-31, PVCT has $577,580 in assets. $7,308,410 in debts.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Restricted cash | - | - | - | 30,542 |
| Cash | 223,883 | 251,291 | 72,479 | 385,929 |
| Prepaid expenses and other current assets | 236,502 | 316,583 | 205,509 | 151,849 |
| Total current assets | 460,385 | 567,874 | 277,988 | 568,320 |
| Equipment and furnishings, less accumulated depreciation of 120,479 and 120,013, respectively | 2,534 | 3,000 | 3,465 | 3,931 |
| Operating lease right-of-use asset | 114,661 | 126,628 | 138,451 | 150,133 |
| Total assets | 577,580 | 697,502 | 419,904 | 722,384 |
| Accounts payable | 815,315 | 716,220 | 1,177,776 | 1,311,038 |
| Accrued interest-Nonrelated Party | 38,300 | 23,540 | 44,133 | 26,344 |
| Accrued interest-Related Party | 119,545 | 120,384 | 97,450 | 121,868 |
| Other accrued expenses | 3,568,311 | 3,161,379 | 2,824,285 | 2,623,420 |
| Notes payable | 161,265 | 217,772 | 105,860 | 54,337 |
| Unearned grant revenue | - | - | - | 0 |
| Convertible notes payable-Nonrelated Party | 980,000 | 870,000 | 1,050,000 | 650,000 |
| Convertible notes payable-Related Party | 1,510,000 | 1,740,000 | 1,125,000 | 1,660,000 |
| Operating lease liability, current portion | 49,025 | 48,083 | 47,152 | 46,232 |
| Total current liabilities | 7,241,761 | 6,897,378 | 6,471,656 | 6,493,239 |
| Notes payable, non-current portion | - | 23,621 | 23,621 | - |
| Operating lease liability, non-current portion | 66,649 | 79,221 | 91,637 | 103,900 |
| Total liabilities | 7,308,410 | 7,000,220 | 6,586,914 | 6,597,139 |
| Preferred stock value-Series DConvertible Preferred Stock | 957 | 957 | 957 | 957 |
| Preferred stock value-Series DOne Convertible Preferred Stock | 14,355 | 14,183 | 13,975 | 13,724 |
| Common stock par value 0.001 per share 1,000,000,000 shares authorized 420,279,879 shares issued and outstanding at march 31, 2026 and december 31, 2025 | 420,280 | 420,280 | 420,280 | 420,280 |
| Additional paid-in capital | 257,043,993 | 256,179,846 | 255,163,053 | 254,131,964 |
| Accumulated other comprehensive loss | -59,906 | -60,191 | -60,327 | -60,361 |
| Accumulated deficit | -264,144,266 | -262,853,812 | -261,688,770 | -260,377,489 |
| Total provectus biopharmaceuticals, inc., stockholders deficit | -6,724,587 | -6,298,737 | -6,150,832 | -5,870,925 |
| Non-controlling interest in subsidiary | -6,243 | -3,981 | -16,178 | -3,830 |
| Total stockholders deficit | -6,730,830 | -6,302,718 | -6,167,010 | -5,874,755 |
| Total liabilities and stockholders deficit | 577,580 | 697,502 | 419,904 | 722,384 |
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)